Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie S Callander

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2026
Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple MyelomaZhubin Gahvari, Natalie S Callander
Current Hematologic Malignancy Reports|May 13, 2021
Progress in the Management of Smoldering Multiple MyelomaTimothy M Schmidt, Natalie S Callander
Oncology (Williston Park, N.Y.)|April 27, 2023
The Management of Relapsed and Refractory Multiple MyelomaZhubin J Gahvari, Natalie S Callander
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2024
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTimothy Schmidt, Zhubin Gahvari, Natalie S Callander
Cancer|December 28, 2020
Clinical effects and applications of the gut microbiome in hematologic malignanciesChristopher R D'Angelo, Sailendharan Sudakaran, Natalie S Callander
European Journal of Haematology|December 15, 2023
Update on the current and future use of CAR-T to treat multiple myelomaZhubin Gahvari, Matthew Brunner, Timothy Schmidt, et al.
Leukemia & Lymphoma|September 28, 2022
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapySusan Bal, Timothy M Schmidt, Luciano J Costa, et al.
Molecular Cancer Research : MCR|May 23, 2022
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug ResistanceChristina Mark, Jay Warrick, Natalie S Callander, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|June 2, 2022
Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolutionChristina Mark, Natalie S Callander, Kenny Chng, et al.
Blood Advances|August 30, 2023
HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MMHae Yeun Chang, Mailee Huynh, Avtar Roopra, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2026
Autologous Hematopoietic Cell Transplantation (AHCT) for the Treatment of Newly Diagnosed Multiple MyelomaZhubin Gahvari, Natalie S Callander
Current Hematologic Malignancy Reports|May 13, 2021
Progress in the Management of Smoldering Multiple MyelomaTimothy M Schmidt, Natalie S Callander
Oncology (Williston Park, N.Y.)|April 27, 2023
The Management of Relapsed and Refractory Multiple MyelomaZhubin J Gahvari, Natalie S Callander
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2024
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTimothy Schmidt, Zhubin Gahvari, Natalie S Callander
Cancer|December 28, 2020
Clinical effects and applications of the gut microbiome in hematologic malignanciesChristopher R D'Angelo, Sailendharan Sudakaran, Natalie S Callander
European Journal of Haematology|December 15, 2023
Update on the current and future use of CAR-T to treat multiple myelomaZhubin Gahvari, Matthew Brunner, Timothy Schmidt, et al.
Leukemia & Lymphoma|September 28, 2022
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapySusan Bal, Timothy M Schmidt, Luciano J Costa, et al.
Molecular Cancer Research : MCR|May 23, 2022
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug ResistanceChristina Mark, Jay Warrick, Natalie S Callander, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|June 2, 2022
Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolutionChristina Mark, Natalie S Callander, Kenny Chng, et al.
Blood Advances|August 30, 2023
HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MMHae Yeun Chang, Mailee Huynh, Avtar Roopra, et al.
Pageof 10